Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226574 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
A Phase 1 study of Intractable Cancer Pain, sponsored by Sorrento Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT03226574 is a Phase 1 study of Intractable Cancer Pain that has completed, run by Sorrento Therapeutics. The registered enrollment target is 17 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT03226574, a Phase 1 study of Intractable Cancer Pain, has completed, sponsored by Sorrento Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult subjects with intractable pain associated with cancer in any area below the mid-thoracic level who meet all other eligibility criteria.
Conditions Studied
Interventions
- DRUG Resiniferatoxin
Study Locations (4)
Florida
- University of Miami/Sylvester Comprehensive Cancer Center - Miami
Massachusetts
- Brigham & Women's Hospital - Boston
North Carolina
- Duke University Medical Center - Durham
Texas
- Hermann Drive Surgical Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2020-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226574
The ClinicalTrials.gov registry entry for NCT03226574 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sorrento Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intractable Cancer Pain appearing as the primary indexed condition, and to 1 intervention - of which Resiniferatoxin is the first listed.
NCT03226574 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03226574 about?
NCT03226574 is a clinical study titled "Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain". The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult subjects with intractable pain associated with cancer in any area below the mid-thoracic level who meet all other eligibility criteria.
What is the current status of trial NCT03226574?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-09-01. Estimated completion is 2020-06-18.
What conditions does trial NCT03226574 study?
This clinical trial studies the following conditions: Intractable Cancer Pain.
What interventions are being tested in trial NCT03226574?
The interventions under investigation include: Resiniferatoxin (DRUG).
Who is sponsoring clinical trial NCT03226574?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03226574 being conducted?
This trial has 4 study locations across Florida, Massachusetts, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.